Over 90% of kidney malignancies are renal cell carcinomas (RCC), which are tumors arising from the renal epithelium. Clear cell RCC (ccRCC) is the most frequent histological subtype and the cause of the majority of kidney cancer-related fatalities. Because of its low 5-year survival rate, poor prognosis, and poor treatment response to chemotherapy and radiation, metastatic RCC (mRCC) is considered a severe condition among kidney cancers. Although different therapies have been tried for mRCC, new therapeutic targets are still needed to overcome the disease. Currently, genomics and transcriptomics studies are being conducted in order to uncover specific genes associated with mRCC. In addition, we were able to apply mass spectrometry-based comparative proteomics, which has become more widely available. Following we performed research to identify the novel progression factors in mRCC based on proteomics approaches, more information about the progression to mRCC using quantitative profiling was identified. In this study, we selected 239 differentially expressed proteins among the 2,905 quantified proteins. We finally chose the 6 target proteins to perform next research.